<DOC>
	<DOCNO>NCT01019408</DOCNO>
	<brief_summary>The purpose study provide strong evidence extended-dose chloroquine treatment falciparum-positive Afghan refugee Northwest Frontier Province ( NWFP ) , Pakistan justification discontinuation policy .</brief_summary>
	<brief_title>Extended-dose Chloroquine ( ECQ ) Resistant Falciparum Malaria Among Afghan Refugees Pakistan</brief_title>
	<detailed_description>To determine whether extended-dose chloroquine provide well cure rate few recrudescence standard chloroquine treatment among Afghan refugee , 163 falciparum patient three Afghan refugee camp recruit 3-day ( CQ 25mg/kg ) 5-day ( CQ 40mg/kg ) treatment arm follow 60 day .</detailed_description>
	<mesh_term>Malaria</mesh_term>
	<mesh_term>Malaria , Falciparum</mesh_term>
	<mesh_term>Chloroquine</mesh_term>
	<mesh_term>Chloroquine diphosphate</mesh_term>
	<criteria>slideconfirmed infection P. falciparum initial parasite density 1000100,000 asexual parasites/μl absence severe malnutrition ability attend stipulate followup visit easy access facility inform consent provide patient parent/guardian absence history hypersensitivity reaction CQ infant six month old pregnancy lactation underlie chronic severe illness patient febrile illness parasitaemia outside range 1000100,000 asexual parasites/µl severe malaria</criteria>
	<gender>All</gender>
	<minimum_age>6 Months</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>November 2009</verification_date>
	<keyword>Clinical Trial</keyword>
	<keyword>Chloroquine</keyword>
	<keyword>Refugees</keyword>
	<keyword>Afghanistan</keyword>
	<keyword>Pakistan</keyword>
</DOC>